Jean François Yale
Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups
Yale, Jean François; Bodholdt, Ulrik; Catarig, Andrei Mircea; Catrina, Sergiu; Clark, Alice; Ekberg, Neda Rajamand; Erhan, Umut; Holmes, Patrick; Knudsen, Søren Tang; Liutkus, Joanne; Sathyapalan, Thozhukat; Schultes, Bernd; Rudofsky, Gottfried
Authors
Ulrik Bodholdt
Andrei Mircea Catarig
Sergiu Catrina
Alice Clark
Neda Rajamand Ekberg
Umut Erhan
Patrick Holmes
Søren Tang Knudsen
Joanne Liutkus
Professor Thozhukat Sathyapalan T.Sathyapalan@hull.ac.uk
Professor of Diabetes, Endocrinology and Metabolism
Bernd Schultes
Gottfried Rudofsky
Abstract
INTRODUCTION: This post hoc pooled analysis of four real-world studies (SURE Canada, Denmark/Sweden, Switzerland and UK) aimed to characterize the use of once-weekly (OW) semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), in patients with type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: The Semaglutide Real-world Evidence (SURE) studies had a duration of ~30 weeks. Changes in glycated hemoglobin (HbA1c) and body weight (BW) were analyzed for the overall population and the following baseline subgroups: GLP-1RA-naïve/GLP-1RA switchers; body mass index <25/≥25-<30/≥30-<35/≥35 kg/m2; age <65/≥65 years; HbA1c <7%/≥7-≤8%/>8-≤9%/>9%; T2D duration <5/≥5-<10/≥10 years. Data for patients achieving treatment targets were analyzed in the overall population and the baseline HbA1c ≥7% subgroup. RESULTS: Of 1212 patients, 960 were GLP-1RA-naïve and 252 had switched to semaglutide from another GLP-1RA. In the overall population, HbA1c was reduced from baseline to end of study (EOS) by -1.1% point and BW by -4.7 kg; changes were significant for all subgroups. There were significantly larger reductions of HbA1c and BW in GLP-1RA-naïve versus GLP-1RA switchers and larger reductions in HbA1c for patients with higher versus lower baseline HbA1c. At EOS, 52.6% of patients in the overall population achieved HbA1c <7%. No new safety concerns were identified in any of the completed SURE studies. CONCLUSIONS: In this pooled analysis, patients with T2D initiating OW semaglutide showed significant improvements from baseline to EOS in HbA1c and BW across various baseline subgroups, including patients previously treated with a GLP-1RA other than semaglutide, supporting OW semaglutide use in clinical practice. TRAIL REGISTRATION NUMBERS: NCT03457012; NCT03631186; NCT03648281; NCT03876015.
Citation
Yale, J. F., Bodholdt, U., Catarig, A. M., Catrina, S., Clark, A., Ekberg, N. R., Erhan, U., Holmes, P., Knudsen, S. T., Liutkus, J., Sathyapalan, T., Schultes, B., & Rudofsky, G. (2022). Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups. BMJ Open Diabetes Research and Care, 10(2), Article e002619. https://doi.org/10.1136/bmjdrc-2021-002619
Journal Article Type | Article |
---|---|
Acceptance Date | Feb 28, 2022 |
Online Publication Date | Apr 5, 2022 |
Publication Date | 2022 |
Deposit Date | Apr 21, 2022 |
Publicly Available Date | Apr 21, 2022 |
Journal | BMJ open diabetes research & care |
Electronic ISSN | 2052-4897 |
Publisher | BMJ Publishing Group |
Peer Reviewed | Peer Reviewed |
Volume | 10 |
Issue | 2 |
Article Number | e002619 |
DOI | https://doi.org/10.1136/bmjdrc-2021-002619 |
Public URL | https://hull-repository.worktribe.com/output/3971010 |
Files
Published article
(1 Mb)
PDF
Publisher Licence URL
http://creativecommons.org/licenses/by-nc/4.0
Copyright Statement
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
You might also like
Molecular Aspects of Cardiovascular Risk Factors
(2024)
Journal Article
Effect of Hypoglycemia and Rebound Hyperglycemia on Proteomic Cardiovascular Risk Biomarkers
(2024)
Journal Article
Downloadable Citations
About Repository@Hull
Administrator e-mail: repository@hull.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search